Ursodeoxycholic acid - Alfa Farmaceutici/sanofi-aventis
Alternative Names: Actigall; Delursan; LJDCA; UDCA; Urso; Urso 500; Urso DS; Urso Forte; Ursobilane; Ursochol; Ursodesoxycholic acid; Ursodiol; Ursolite; UrsosanLatest Information Update: 05 Nov 2021
At a glance
- Originator Alfa Farmaceutici; sanofi-aventis
- Developer AbbVie; Adare Pharmaceuticals; Axcan Pharma; Estedi; Mitsubishi Tanabe Pharma Corporation; Novartis; Procter & Gamble Pharmaceuticals Spain; sanofi-aventis; Zambon Company SpA
- Class Cholic acids; Gallstone therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cholelithiasis; Liver disorders; Primary biliary cirrhosis; Primary sclerosing cholangitis
- No development reported Hypercholesterolaemia; Liver transplant rejection
- Discontinued Colorectal cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 09 Apr 2021 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
- 09 Apr 2021 Discontinued - Phase-II/III for Colorectal cancer in USA (PO)
- 08 May 2020 Allergan has been acquired and merged into AbbVie